Delivery Order SPE2DR25D1200-SPE2DR26FMK5B
- Not listed
- The Defense Logistics Agency awarded a $44,057.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injector pens on December 11, 2025, with an ultimate completion date of December 12, 2025. This non-set-aside contract represents a competitive award to the prime contractor, which is headquartered in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $33,600.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of January 21, 2026. This competitive award with no set-aside designation represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s substantial Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2031. The contract...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $30,136.70 by the Defense Logistics Agency (DLA) on August 26, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors. This firm fixed-price delivery order, with an ultimate completion date of August 27, 2025, represents a competitively awarded contract with no set-aside designation. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a $88,817.52 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of December 17, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a continuation order under AmerisourceBergen's larger pharmaceutical supply relationship with the federal government. The place of performance is listed as Conshohocken, Pennsylvania, where...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a $11,772.16 firm fixed-price delivery order for Repatha 140 mg/ml SureClick auto-injectors on January 13, 2026, with an ultimate completion date of January 14, 2026. The Defense Logistics Agency funded this award, which carries no set-aside designation, indicating it was competitively awarded. This delivery order falls under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $26,066.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of December 31, 2025. This non-set-aside contract was competitively awarded on December 30, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. REPATHA is a specialty pharmaceutical product used to treat high cholesterol, and this delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,232.28 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 13, 2025. This competitive, firm fixed-price delivery order represents a continuation of pharmaceutical supply under AmerisourceBergen's existing contract vehicle with DLA. The award carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $16,007.47 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 2, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order valued at $8,826.84 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical product will...
- The Defense Logistics Agency awarded a $11,808.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of December 10, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. REPATHA is a prescription medication used to treat high cholesterol, and...
- SPE2DR25D1200Indefinite Delivery Contract
- SPE2DR25D1200-SPE2DR26FMK5BDelivery Order
Amerisourcebergen Drug Corp was awarded a delivery order valued at $30,765.83 by the Defense Logistics Agency (DLA) on January 20, 2026, for the supply of REPATHA 140 mg/ml SureClick auto-injector pens. This firm fixed-price, non-set-aside contract will be performed at the company's Conshohocken, Pennsylvania location, with an ultimate completion date of January 21, 2026. The delivery order is issued under Amerisourcebergen Drug Corp's parent company, Cencora, Inc. (doing business as Amerisourcebergen), which holds a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2031, serving as the primary vehicle for pharmaceutical and medical supply deliveries to military healthcare programs globally. REPATHA is a cholesterol-lowering monoclonal antibody used in cardiovascular disease management, indicating this delivery order supports the medical supply needs of the Department of Defense healthcare systems. The non-set-aside status demonstrates that this award was made through full and open competition, reflecting Amerisourcebergen Drug Corp's established capability to fulfill federal pharmaceutical procurement requirements efficiently and reliably across multiple therapeutic domains for military personnel and related healthcare beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $30.8k | 1/19/26 |